CEO Chris Viehbacher highlighted Biogen's evolving portfolio, with newer products such as LEQEMBI, SKYCLARYS, and ZURZUVAE now comprising 45% of product revenue. He emphasized the approval of ...

Biogen BIIB and Japanese partner Eisai announced that the FDA has accepted Eisai’s supplemental biologics license application (sBLA) seeking approval for a maintenance intravenous (“IV ...

Biogen raised its full-year 2024 outlook after releasing its Q2 earnings report Thursday, which showed sales of its Alzheimer’s drug Leqembi and several newly launched drugs were slightly better than ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Biogen on Wednesday posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi ...

Dec 3 (Reuters) - Biogen (BIIB.O), opens new tab expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company ...

U.S. regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...

The test potentially makes it easier to find and treat patients with the memory-robbing disease. Read more at straitstimes.com. Read more at straitstimes.com.

A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. | A dementia-focused transatlantic venture capital initiative has secured $269 ...